Comparable effectiveness of MF59®-adjuvanted and high-dose quadrivalent inactivated influenza vaccines for prevention of test-confirmed influenza during the 2022-2023 influenza season

This publication has 27 references indexed in Scilit:

• Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017–2020 influenza seasons
  International Journal of Infectious Diseases, 2024
• Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: a systematic review and meta-analysis
  International Journal of Infectious Diseases, 2022
• Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience
  International Journal of Infectious Diseases, 2019
• Reconciling estimates of the global influenza burden
  The Lancet Respiratory Medicine, 2019
• Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis
  Expert Review of Vaccines, 2018
• Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study
  The Lancet, 2018
• Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
  Statistics in Medicine, 2015
• Using claims data to predict dependency in activities of daily living as a proxy for frailty
  Pharmacoepidemiology and Drug Safety, 2014
• Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
  New England Journal of Medicine, 2014
• The mechanism of action of MF59 – An innately attractive adjuvant formulation
  Vaccine, 2012